Increased CMV infection following nonmyeloablative allogeneic stem cell transplantation: A search for the guilty [3]

Blood

Volumn 101, Issue 5, 2003, Pages 2071-2072

  Chakrabarti, Supamo ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CAMPATH 1G; CARMUSTINE; CYTARABINE; ETOPOSIDE; FLUDARABINE; LYMPHOCYTE ANTIBODY; MELPHALAN; UNCLASSIFIED DRUG;

CANCER INCIDENCE; CANCER RECURRENCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG MECHANISM; FISHER EXACT TEST; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION COMPLICATION; LETTER; LYMPHOCYTE COUNT; LYMPHOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RADIATION DOSE; STATISTICAL SIGNIFICANCE; STEM CELL TRANSPLANTATION; VIRUS INFECTION; VIRUS REACTIVATION; WHOLE BODY RADIATION;

EID: 0037370792     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-11-3588     Document Type: Letter

References (8)

1. Bainton RD, Byrne JL, Davy BJ, Russell NH. CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath. Blood. 2002;100:3843-3844.
2. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1 H in delaying immune reconstitution. Blood. 2002;99:4357-4363.
3. Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002;100:3121-3127.
4. Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood. 2002;99:1978-1985.
5. Mossad SB, Avery RK, Longworth DL, et al. Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001;28:491-495.
6. Martino R, Caballero MD, Canals C, et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001;28:341-347.
7. Mohty M, Faucher C, Vey N, et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant. 2000;26:251-255.
8. Rebello P, Cwynarsky K, Varughese M, et al. Pharmacokinetics of Campath-1H in bone marrow transplant patients. Cytotherapy. 2001;3:261-267.